Fidelity Investments
ORIC icon

Fidelity Investments’s Oric Pharmaceuticals ORIC Stock Holding History

Fidelity Investments’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.5M Buy
2,635,475
+201,395
+8% +$1.83M ﹤0.01% 1741
2026
Q1 		$30.8M Sell
2,434,080
-44,842
-2% -$509K ﹤0.01% 1609
2025
Q4 		$20.3M Sell
2,478,922
-49,126
-2% -$565K ﹤0.01% 1768
2025
Q3 		$30.3M Buy
2,528,048
+57,991
+2% +$610K ﹤0.01% 1624
2025
Q2 		$25.1M Sell
2,470,057
-10,363
-0.4% -$69.6K ﹤0.01% 1622
2025
Q1 		$13.8M Buy
2,480,420
+12,611
+0.5% +$110K ﹤0.01% 1800
2024
Q4 		$19.9M Sell
2,467,809
-1,911,010
-44% -$17.5M ﹤0.01% 1728
2024
Q3 		$44.9M Sell
4,378,819
-541,541
-11% -$5.35M ﹤0.01% 1424
2024
Q2 		$34.8M Sell
4,920,360
-104,240
-2% -$933K ﹤0.01% 1452
2024
Q1 		$69.1M Sell
5,024,600
-1,977,508
-28% -$23.5M ﹤0.01% 1198
2023
Q4 		$64.4M Buy
7,002,108
+3,869,914
+124% +$28M ﹤0.01% 1191
2023
Q3 		$18.9M Sell
3,132,194
-600,054
-16% -$4.92M ﹤0.01% 1603
2023
Q2 		$29M Sell
3,732,248
-274,851
-7% -$1.56M ﹤0.01% 1483
2023
Q1 		$22.8M Sell
4,007,099
-9,509
-0.2% -$49.7K ﹤0.01% 1558
2022
Q4 		$23.7M Sell
4,016,608
-331,784
-8% -$1.12M ﹤0.01% 1552
2022
Q3 		$13.9M Sell
4,348,392
-6,790
-0.2% -$27.2K ﹤0.01% 1758
2022
Q2 		$19.5M Sell
4,355,182
-63,231
-1% -$252K ﹤0.01% 1654
2022
Q1 		$23.6M Sell
4,418,413
-1,488,866
-25% -$13.4M ﹤0.01% 1711
2021
Q4 		$86.8M Buy
5,907,279
+9,627
+0.2% +$150K 0.01% 1173
2021
Q3 		$123M Buy
5,897,652
+393,280
+7% +$7.97M 0.01% 1011
2021
Q2 		$97.4M Buy
5,504,372
+120
+0% +$2.63K 0.01% 1126
2021
Q1 		$135M Buy
5,504,252
+51,905
+1% +$1.64M 0.01% 954
2020
Q4 		$185M Buy
5,452,347
+959,019
+21% +$27.5M 0.02% 778
2020
Q3 		$111M Buy
4,493,328
+286,380
+7% +$6.82M 0.01% 864
2020
Q2 		$139M Buy
+4,206,948
New +$134M 0.02% 741

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments's ORIC Position: Q2 2026 in Review

Fidelity Investments increased its Oric Pharmaceuticals (ORIC) stake by 8.3% in Q2 2026, buying an estimated $1.83M and bringing the position to 2,635,475 shares worth $28.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1741.

Fidelity Investments first reported a position in ORIC in Q2 2020 and has held it in 25 quarters since. The position peaked at $185M in Q4 2020. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Fidelity Investments held 2,635,475 shares of Oric Pharmaceuticals worth $28.5M as of Q2 2026.
  • Fidelity Investments bought 201,395 Oric Pharmaceuticals shares in Q2 2026, an estimated $1.83M.
  • Oric Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1741 holding.
  • Fidelity Investments first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Fidelity Investments's Oric Pharmaceuticals position peaked at $185M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.